NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05252390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT05252390
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Enrollment
- 82 participants
Conditions and interventions
Conditions
- Advanced Solid Tumor
- Breast Cancer
- Breast Carcinoma
- Breast Tumor
- Cancer of Breast
- Cancer of Ovary
- Cancer of Pancreas
- Cancer of Prostate
- Cancer of the Breast
- Cancer of the Ovary
- Cancer of the Pancreas
- Cancer of the Prostate
- Castrate Resistant Prostate Cancer
- Castration Resistant Prostatic Cancer
- Castration Resistant Prostatic Neoplasms
- Ovarian Cancer
- Ovary Cancer
- Ovary Neoplasm
- Pancreas Cancer
- Pancreas Neoplasm
- Pancreatic Cancer
- Prostate Cancer
- Prostate Neoplasm
- Prostatic Cancer
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Triple-negative Breast Cancer
Interventions
- Enzalutamide Drug
- NUV-868 Drug
- Olaparib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2022
- Primary completion
- Jul 14, 2024
- Completion
- Jul 14, 2024
- Last update posted
- Nov 5, 2025
2022 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Ellison Institute of Technology | Los Angeles | California | 90064 | — |
| Rocky Mountain Cancer Centers, LLP | Aurora | Colorado | 80012 | — |
| Rocky Mountain Cancer Centers, LLP | Lone Tree | Colorado | 80124 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Laura & Isaac Perlmutter Cancer Center - NYU Langone Health | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| NEXT Virginia | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05252390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05252390 live on ClinicalTrials.gov.